



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION/MOC EXAMINATION IN NEUROLOGY

The American Board of Psychiatry and Neurology, Inc. (ABPN) has issued new, two-dimensional content specifications for the psychiatry, neurology and child neurology continuing certification/MOC examinations. Questions for the psychiatry, neurology and child neurology continuing certification examinations will conform to these new content specifications.

Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice.

The psychiatry, neurology and child neurology continuing certification content specifications can be accessed from the [Specialty MOC Exams section](#) of our website.

Candidates should use the new detailed content specifications as a guide to prepare for a continuing certification/MOC examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format.

The American Board of Psychiatry and Neurology, Inc. is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes.

For more information, please contact us at questions@abpn.com or visit our website at www.abpn.com.



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION/MOC EXAMINATION IN NEUROLOGY Content Blueprint

| | | |
|--|--|-------|
| Number of questions: 220 | | |
| Dimension 1 | | |
| Neurologic Disorders and Topics | | |
| 01. | Headache and pain disorders | 8-12% |
| 02. | Epilepsy and episodic disorders | 8-12% |
| 03. | Sleep disorders | 3-5% |
| 04. | Genetic and developmental disorders | 6-8% |
| 05. | Vascular neurology | 8-12% |
| 06. | Neuromuscular diseases | 8-12% |
| 07. | Movement disorders | 8-12% |
| 08. | Neuroimmunologic and paraneoplastic disorders of the CNS | 8-12% |
| 09. | Neuroinfectious diseases | 2-4% |
| 10. | Brain and spinal trauma | 2-4% |
| 11. | Neuro-ophthalmologic and neuro-otologic disorders | 2-4% |
| 12. | Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents | 3-5% |
| 13. | Neuro-oncologic disorders | 3-5% |
| 14. | Behavioral neurology and neurocognitive disorders | 7-9% |
| 15. | Psychiatric disorders | 1-2% |
| 16. | Autonomic nervous system disorders | 1-3% |
| 17. | Normal structure, process, and development through the life cycle | 1-2% |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION/MOC EXAMINATION IN NEUROLOGY Content Blueprint

| | | |
|--|---|--------|
| Number of questions: 220 | | |
| Dimension 2 | | |
| Physician Competencies and Mechanisms | | |
| | | |
| A. | Neuroscience and mechanism of disease | 4-6% |
| B. | Clinical aspects of neurologic disease | 22-28% |
| C. | Diagnostic procedures | 27-33% |
| D. | Treatment | 27-33% |
| E. | Interpersonal and communication skills | 2-3% |
| F. | Professionalism | 2-3% |
| G. | Practice-based learning and improvement | 2-3% |
| H. | Systems-based practice | 2-3% |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION/MOC EXAMINATION IN NEUROLOGY Content Outline

| |
|---|
| Dimension 1 |
| Neurologic Disorders and Topics |
| 01. Headache and pain disorders |
| A. Headache |
| 01. Primary headaches |
| a. Migraine |
| b. Tension-type headache |
| c. Cluster headache and other trigeminal autonomic cephalalgias |
| d. Other primary headaches (exertional headache, etc.) |
| 02. Secondary headaches |
| a. Headache due to head and neck trauma (posttraumatic headache) |
| b. Headache due to cranial or cervical vascular disorder (thunderclap headache, giant cell arteritis, arterial dissection, cerebral hemorrhage, ischemia) |
| c. Headache due to nonvascular intracranial disorder (hydrocephalus, idiopathic intracranial hypertension, low-CSF-pressure headaches, tumors) |
| d. Headache due to infection |
| e. Headache due to a substance or its withdrawal |
| f. Headache or facial pain due to disorder of cranium, neck, eyes, ears, nose, sinuses, and teeth |
| g. Headache due to psychiatric disorder |
| 03. Cranial neuralgia, central and primary facial pain (trigeminal neuralgia, idiopathic facial pain, post-herpetic neuralgia) |
| B. Pain disorders |
| 01. Neuropathic pain (small fiber neuropathy, post-herpetic neuralgia, radiculopathies) |
| 02. Central pain syndromes (thalamic, phantom, etc.) |
| 03. Complex regional pain syndromes |
| 02. Epilepsy and episodic disorders |
| A. Generalized seizures |
| 01. Tonic-clonic |
| 02. Absence |
| a. Typical |
| b. Atypical |
| c. Absence with special features |
| 03. Myoclonic |
| 04. Clonic |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 05. Tonic |
| 06. Atonic |
| B. Focal seizures |
| 01. Simple partial |
| 02. Complex partial |
| 03. Focal evolving to bilateral convulsive seizure |
| C. Electro-clinical syndromes |
| 01. Neonatal period |
| a. Benign familial neonatal seizures (BFNS) |
| b. Early myoclonic encephalopathy (EME) |
| c. Ohtohara syndrome |
| 02. Infancy |
| a. West syndrome |
| b. Myoclonic epilepsy in infancy |
| c. Benign infantile seizures |
| d. Benign familial infantile seizures |
| e. Dravet syndrome |
| f. Myoclonic encephalopathy in nonprogressive disorders |
| 03. Childhood |
| a. Febrile seizures (FS+) |
| b. Early benign childhood occipital epilepsy (Panayiotopoulos type) |
| c. Epilepsy with myoclonic-atonic seizures |
| d. Benign epilepsy with centrotemporal spikes (BECTS) |
| e. Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) |
| f. Late-onset childhood occipital epilepsy (Gastaut type) |
| g. Epilepsy with myoclonic absences |
| h. Lennox-Gastaut syndrome |
| i. Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS) including Landau-Kleffner syndrome |
| j. Childhood absence epilepsy |
| 04. Adolescence through adult |
| a. Juvenile absence epilepsy (JAE) |
| b. Juvenile myoclonic epilepsy (JME) |
| c. Epilepsy with generalized tonic-clonic seizures alone |
| d. Progressive myoclonic epilepsies (PME) |
| e. Autosomal dominant partial epilepsy with auditory features (ADPEAF) |
| f. Other familial temporal lobe epilepsies |
| D. Less specific age relationship |
| 01. Familial focal epilepsy with variable foci |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 02. Reflex epilepsies |
| E. Distinctive constellations |
| 01. Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS) |
| 02. Rasmussen syndrome |
| 03. Gelastic seizures with hypothalamic hamartoma |
| F. Epilepsies attributed to and organized by structural-metabolic causes |
| 01. Structural, including tumors in vascular malformations |
| 02. Infection |
| 03. Trauma |
| 04. Perinatal insults |
| 05. Malformations of cortical development, including neurocutaneous syndromes |
| 06. Mitochondrial and metabolic disorders |
| G. Epilepsies of unknown cause |
| H. Conditions with epileptic seizures traditionally not diagnosed as a form of epilepsy |
| 01. Benign neonatal seizures (BNS) |
| 02. Febrile seizures (FS) |
| I. Non-epileptic paroxysmal disorders |
| 01. Breath-holding spells |
| 02. Cardiac etiologies (e.g., prolonged QT interval) |
| 03. Syncope, convulsive and nonconvulsive |
| 04. Gastroesophageal reflux and Sandifer syndrome |
| 05. Gratification phenomena and masturbation |
| 06. Shuddering/shivering |
| 07. Acute confusional migraine |
| 08. Benign infant myoclonus |
| 09. Non-epileptic psychogenic seizures |
| J. Status epilepticus |
| 03. Sleep disorders |
| A. Insomnia |
| 01. Psychological insomnia |
| 02. Inadequate sleep hygiene |
| B. Sleep-disordered breathing |
| 01. Obstructive sleep apnea |
| 02. Central apnea syndromes |
| 03. Sleep-related hypoventilation disorders |
| C. Central disorders of hypersomnolence |
| 01. Narcolepsy (with and without cataplexy) |
| 02. Kleine-Levin syndrome |
| 03. Hypersomnia due to a medical condition |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 04. Insufficient sleep syndrome |
| D. Circadian rhythm sleep-wake disorders |
| 01. Delayed sleep-wake phase disorder |
| 02. Advanced sleep-wake phase disorder |
| 03. Irregular sleep-wake rhythm disorder |
| 04. Non-24-hour sleep-wake phase disorder |
| E. Parasomnias |
| 01. NREM-related parasomnias |
| a. Arousal disorders, including sleepwalking, sleep terrors, and confusional arousals |
| i. Sleepwalking |
| ii. Sleep terrors |
| iii. Confusional arousals |
| b. Sleep-related eating disorder |
| 02. REM-related parasomnias |
| a. REM behavior disorder |
| b. Recurrent isolated sleep paralysis |
| c. Nightmare disorder |
| 03. Other |
| a. Exploding head syndrome |
| b. Sleep-related hallucinations |
| c. Sleep enuresis |
| d. Parasomnia due to a general medical disorder |
| e. Medication/substance-related parasomnia |
| f. Unspecified parasomnia |
| F. Sleep-related movement disorders |
| 01. Periodic limb movements of sleep |
| 02. Sleep-related limb cramps |
| 03. Sleep-related bruxism |
| 04. Benign myoclonus of infancy |
| G. Sleep disorders in other conditions |
| 01. Sleep disturbances in movement conditions |
| a. Parkinson disease |
| b. Multisystem atrophy |
| c. Dementia with Lewy bodies |
| d. Spinocerebellar degeneration |
| e. Huntington disease |
| 02. Amyotrophic lateral sclerosis |
| 03. Alzheimer disease |
| 04. Effects of sleep disorders on cardiovascular/cerebrovascular risk factors |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Hypertension |
| b. Atrial fibrillation |
| c. Congestive heart failure |
| d. Myocardial infarction |
| e. Stroke |
| 04. Genetic and developmental disorders |
| A. Inherited metabolic disorders |
| 01. Disorders of amino acid metabolism |
| a. Phenylketonuria |
| b. Nonketotic hyperglycemia |
| c. Other |
| 02. Disorders of urea cycle metabolism |
| a. Ornithine transcarbamylase |
| b. Other |
| 03. Disorders of sulfur amino acids |
| a. Homocystinuria |
| b. Other |
| 04. Disorders of amino acid transport |
| a. Hartnup disease |
| b. Lowe syndrome |
| c. Other |
| 05. Disorders of carbohydrate metabolism and transport |
| a. Galactosemia |
| b. Glucose transporter deficiency |
| c. Other |
| 06. Organic acidurias |
| a. Methylmalonic acidurias |
| b. Glutaric acidurias |
| c. Other |
| 07. Disorders of fatty acid oxidation |
| 08. Disorders of purine metabolism |
| a. Lesch-Nyhan syndrome |
| b. Other |
| B. Lysosomal disorders |
| 01. Glycogen storage diseases |
| a. Pompe disease |
| b. Mucopolysaccharidoses |
| c. Other |
| 02. Gangliosidoses |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Tay-Sachs disease |
| b. Other |
| 03. Gaucher disease |
| 04. Fabry disease |
| 05. Niemann-Pick disease |
| 06. Other |
| C. Leukodystrophies |
| 01. Adrenoleukodystrophy |
| 02. Pelizaeus-Merzbacher disease |
| 03. Canavan disease |
| 04. Alexander disease |
| 05. Metachromatic leukodystrophy |
| 06. Krabbe disease |
| 07. Other |
| D. Additional disorders |
| 01. Rett syndrome |
| 02. Mitochondrial disorders |
| 03. Peroxisomal disorders |
| 04. Other |
| E. Chromosomal disorders |
| 01. Autosomal abnormalities |
| a. Down syndrome (trisomy 21) |
| b. Trisomy 13 |
| c. Cri du chat syndrome |
| d. Other |
| F. Disorders of brain and spine development |
| 01. Anencephaly |
| 02. Myelomeningocele and encephalocele |
| 03. Chiari malformations |
| 04. Other cord dysraphism |
| a. Syringomyelia |
| b. Diastematomyelia |
| 05. Cerebellar malformations |
| 06. Skull malformations, including craniosynostosis |
| 07. Brain malformations |
| a. Holoprosencephaly |
| b. Septo-optic dysplasia |
| c. Schizencephaly |
| d. Lissencephaly and other migrational abnormalities |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| e. Agenesis of the corpus callosum |
| f. Hemimegalencephaly |
| 08. Microencephaly and micrencephaly |
| 09. Macroencephaly and megalencephaly |
| 10. Hydrocephalus |
| G. Neurocutaneous syndromes |
| 01. Neurofibromatosis 1 and 2 |
| 02. Tuberous sclerosis |
| 03. Sturge-Weber syndrome |
| 04. Ataxia-telangiectasia |
| 05. Von Hippel-Lindau disease |
| 06. Incontinentia pigmenti |
| 07. Other |
| H. Cerebral palsy |
| 01. Spastic |
| 02. Dyskinetic |
| 05. Vascular neurology |
| A. Ischemic stroke (cerebral infarction and transient ischemic attack) |
| 01. Atherosclerosis |
| a. Large-artery |
| b. Small-artery |
| 02. Cardioembolic |
| 03. Arterial dissection |
| 04. Other vasculopathies, including hypercoagulability (thrombophilia) and vasculitis |
| B. Intracerebral hemorrhage |
| 01. Chronic hypertension |
| 02. Vascular malformations |
| 03. Bleeding diatheses and antithrombotic agents |
| 04. Amyloid angiopathy |
| 05. Tumors |
| C. Subarachnoid hemorrhage |
| 01. Aneurysm |
| 02. Vascular malformations |
| D. Cerebral venous thrombosis |
| 01. Pregnancy and puerperium |
| 02. Hypercoagulability (thrombophilia) |
| E. Cerebrovascular constriction, including reversible cerebrovascular constriction syndrome and posterior reversible encephalopathy syndrome (PRES) |
| F. Sickle cell disease |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 06. Neuromuscular diseases |
| A. Motor neuron disorders |
| 01. Amyotrophic lateral sclerosis (sporadic) |
| 02. Genetic |
| a. Familial amyotrophic lateral sclerosis |
| b. Spinal muscular atrophy |
| c. Kennedy disease |
| d. Tay-Sachs disease |
| 03. Focal, including Hirayama disease |
| 04. Paraneoplastic |
| B. Spinal root disorders |
| 01. Cervical |
| 02. Thoracic |
| 03. Lumbosacral |
| 04. Polyradiculopathy |
| 05. Specific etiologies |
| a. Diabetes |
| b. Segmental herpes zoster and post-herpetic neuralgia |
| C. Plexopathies |
| 01. Brachial |
| a. Traumatic (neonatal, penetrating injury) |
| b. Radiation-induced |
| c. Neuralgic amyotrophy (brachial neuritis) |
| d. Hereditary neuralgic amyotrophy |
| e. Neoplastic |
| 02. Lumbosacral |
| a. Traumatic (hematoma, ischemic) |
| b. Radiation-induced |
| c. Diabetic radiculo-plexo-neuropathy |
| d. Neoplastic |
| D. Peripheral nerve disorders |
| 01. Mononeuropathies |
| a. Median |
| b. Ulnar |
| c. Radial |
| d. Musculocutaneous |
| e. Axillary |
| f. Spinal accessory |
| g. Suprascapular |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| h. Sciatic |
| i. Peroneal |
| j. Tibial |
| k. Femoral |
| l. Obturator |
| m. Facial |
| n. Trigeminal |
| o. Other |
| 02. Mononeuropathy multiplex |
| a. Diabetic |
| b. Vasculitic |
| 03. Polyneuropathy |
| a. Hereditary |
| i. Demyelinating |
| (a) CMT1a |
| (b) CMTX |
| (c) Hereditary neuropathy with tendencies to pressure palsy (HNPP) |
| (d) Refsum disease |
| ii. Axon loss (CMT2) |
| iii. TTR amyloid polyneuropathy |
| iv. Porphyric neuropathy |
| b. Acquired |
| i. Demyelinating |
| (a) Acute inflammatory demyelinating polyneuropathy (AIDP) |
| (i) Guillain-Barré syndrome |
| (ii) Miller Fisher variant (GQ1b antibody) |
| (iii) Acute motor axonal neuropathy (AMAN) |
| (iv) Acute motor and sensory axonal neuropathy (AMSAN) |
| (b) Chronic inflammatory demyelinating polyneuropathy (CIDP) |
| (c) Multifocal mononeuropathy with conduction block |
| ii. Metabolic |
| (a) Diabetic |
| (b) Nutritional |
| (i) Vitamin B ₆ deficiency |
| (ii) Vitamin B ₁₂ deficiency |
| (iii) Copper deficiency |
| (iv) Alcohol |
| (v) Hypervitaminosis B ₆ |
| iii. Toxic |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| (a) Arsenic, lead, thallium |
| (b) n-Hexane |
| (c) Organophosphates |
| (d) Drug-induced |
| (i) Isoniazide |
| (ii) Metronidazole |
| (iii) Nitrofurantoin |
| (iv) Chloroquine/hydroxychloroquine |
| (v) Lithium |
| (vi) Other |
| (e) Other |
| iv. Immune/inflammatory |
| (a) Paraneoplastic |
| (b) Amyloidosis |
| (c) Sarcoidosis |
| (d) Paraproteinemic |
| v. Small-fiber sensory polyneuropathy |
| c. Dorsal root ganglion disorders |
| i. Nutritional/toxic, including hypervitaminosis B ₆ |
| ii. Autoimmune/inflammatory |
| (a) Hu antibody syndrome |
| (b) Connective tissue disease (Sjogren syndrome) |
| iii. Friedreich ataxia |
| E. Neuromuscular junction transmission disorders |
| 01. Myasthenia gravis |
| 02. Lambert-Eaton myasthenic syndrome |
| 03. Botulism |
| 04. Congenital/hereditary myasthenia |
| F. Muscle disorders |
| 01. Muscular dystrophies |
| a. Duchenne/Becker |
| b. Facioscapulohumeral |
| c. Limb-girdle |
| i. Calpain LGMD 2A |
| ii. Dysferlin LGMD 2B (including distal presentation) |
| iii. Sarcoglycan LGMD 2C-F |
| iv. FKRP LGMD 2I |
| d. Myotonic |
| i. Myotonic dystrophy 1 (including distal presentation) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| ii. Myotonic dystrophy 2 |
| e. Oculopharyngeal |
| f. Myofibrillar (including distal presentation) |
| 02. Congenital myopathies |
| a. Central core |
| b. Nemaline |
| c. Centronuclear/myotubular (including distal presentation) |
| 03. Metabolic myopathies |
| a. Mitochondrial |
| i. Myoclonic epilepsy with ragged red fibers (MERRF) |
| ii. Mitochondrial myopathy, lactic acid, and stroke (MELAS) |
| iii. Kearns-Sayre syndrome |
| iv. Other |
| b. Glycogenoses |
| i. Pompe disease |
| ii. Myophosphorylase deficiency (McArdle disease) |
| c. Lipidoses |
| i. Carnitine deficiency |
| ii. Carnitine palmitoyltransferase 2 deficiency (CPT2) |
| d. Periodic paralyses |
| i. Hypokalemic |
| ii. Hyperkalemic |
| 04. Acquired myopathies |
| a. Inflammatory myopathies |
| i. Polymyositis |
| ii. Dermatomyositis |
| iii. Inclusion body myositis |
| (a) Sporadic (including distal presentation) |
| (b) Hereditary (including distal presentation) |
| iv. Sarcoidosis |
| v. HIV |
| b. Critical illness myopathy |
| c. Toxic/drug-induced myopathy |
| i. HMG-CoA reductase |
| ii. Alcohol |
| iii. Chloroquine/hydroxychloroquine |
| iv. Corticosteroids |
| v. Colchicine |
| d. Metabolic/endocrine |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| i. Hypothyroid |
| ii. Hyperthyroid |
| iii. Hypokalemic |
| 05. Rhabdomyolysis |
| G. Hyper-excitability disorders |
| 01. Stiff-person syndromes |
| 02. Potassium channelopathies (Isaac syndrome) |
| 07. Movement disorders |
| A. Parkinson disease and parkinsonism |
| 01. Neurodegenerative |
| a. Diffuse Lewy body disease |
| b. Multiple system atrophy |
| c. Progressive supranuclear palsy |
| d. Corticobasal degeneration |
| 02. Post-traumatic parkinsonism |
| 03. Vascular parkinsonism |
| 04. Drug-induced parkinsonism |
| 05. Hydrocephalus and normal-pressure hydrocephalus |
| 06. Juvenile parkinsonism |
| B. Tremor |
| 01. Essential tremor |
| 02. Physiological tremor |
| 03. Drug-induced tremor |
| C. Chorea |
| 01. Huntington disease |
| 02. Sydenham chorea |
| 03. Drug-induced chorea |
| 04. Chorea gravidarum |
| 05. Neuroanthocytosis |
| D. Ballism and athetosis |
| E. Dystonia |
| 01. Focal dystonia |
| 02. Childhood-onset dystonia |
| 03. <i>DYT1</i> dystonia |
| 04. Myoclonic dystonia |
| F. Wilson disease |
| G. Neuroleptic-induced syndromes, acute and chronic |
| 01. Acute dystonic reaction |
| 02. Tardive syndromes |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Tardive dyskinesia |
| b. Tardive dystonia |
| c. Tardive akathisia |
| H. Tic disorders |
| 01. Tourette syndrome |
| 02. Other |
| I. Myoclonus |
| 01. Essential myoclonus |
| 02. Post-hypoxic myoclonus |
| J. Other paroxysmal disorders |
| 01. Hemifacial spasm |
| 02. Dyskinesias |
| 03. Restless legs syndrome |
| K. Ataxia |
| 01. Spinocerebellar ataxias |
| 02. Friedreich ataxia |
| 03. Vitamin |
| 04. Paroxysmal ataxia |
| L. Psychogenic movement disorders |
| 01. Psychogenic tremor |
| 02. Psychogenic dystonia |
| 03. Psychogenic gait disturbance and ataxia |
| M. Critical care |
| 01. Acute parkinsonism |
| 02. Neuroleptic malignant syndrome |
| 03. Serotonin syndrome |
| 04. Dystonic storm |
| 05. Ballism |
| 06. Tic status |
| 08. Neuroimmunologic and paraneoplastic disorders of the CNS |
| A. Demyelinating disease |
| 01. Multiple sclerosis |
| 02. Multiple sclerosis variants (neuromyelitis optica [Devic disease], concentric sclerosis) |
| 03. Acute disseminated encephalomyelitis |
| 04. Transverse myelitis |
| B. CNS vasculitis |
| 01. Primary angiitis of the CNS |
| 02. Secondary CNS vasculitis |
| a. Systemic vasculitides (giant cell arteritis, polyarteritis nodosa, microscopic |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| polyangiitis, Behçet disease) |
| b. Systemic autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, sarcoidosis) |
| c. Infectious vasculitis (varicella zoster) |
| d. Substance-induced vasculitis (amphetamines, cocaine) |
| e. Vasculitis mimics (Susac syndrome, Sneddon syndrome, RCVS) |
| 09. Neuroinfectious diseases |
| A. Bacterial infections |
| 01. Meningitis |
| a. Neonatal |
| i. E. coli |
| ii. Streptococcus |
| iii. Listeria |
| iiii. Other |
| b. Childhood |
| i. Hemophilus influenza |
| ii. Streptococcus pneumonia |
| iii. Other |
| c. Adolescent |
| i. Neisseria meningitis |
| ii. Other |
| d. Adult |
| i. Streptococcus pneumonia |
| ii. Listeria |
| iii. Other |
| 02. Brain abscess |
| 03. Systemic infections with neurologic effects |
| a. Lyme disease |
| b. Syphilis |
| c. Diphtheria |
| d. Tetanus |
| e. Whipple disease |
| B. Fungal infections |
| 01. Meningitis |
| a. Cryptococcus |
| b. Histoplasmosis |
| c. Coccidiomycosis |
| d. Other |
| 02. Cerebritis |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| a. Aspergillosis |
| b. Phycomycosis |
| c. Other |
| C. Mycobacteria, including tuberculosis |
| D. Viral infections |
| 01. Meningitis |
| 02. Encephalitis and myelitis |
| a. West Nile |
| b. Herpes simplex |
| c. Herpes zoster |
| d. Arbovirus |
| e. Rabies |
| f. HIV |
| g. Progressive multifocal leukoencephalopathy |
| h. Polio |
| i. Other |
| E. Protozoan infections |
| 01. Toxoplasmosis |
| 02. Naegleria |
| 03. Trypanosomiasis |
| 04. Other |
| F. Parasitic infections |
| 01. Cysticercosis |
| 02. Other |
| G. Prion infections |
| 10. Brain and spinal trauma |
| A. Brain trauma |
| 01. Cerebral concussion, including chronic traumatic encephalopathy |
| 02. Diffuse axonal injury |
| 03. Cerebral contusion |
| 04. Traumatic hemorrhage |
| a. Epidural hematoma |
| b. Subdural hematoma |
| c. Traumatic subarachnoid hematoma |
| B. Spinal trauma and skeletal disease |
| 01. Spinal cord contusion and transection |
| 02. Spinal epidural hematoma |
| 03. Spinal cord compression from disc or bone |
| 04. Spinal cord herniation |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 05. Associated autonomic disorders |
| 11. Neuro-ophthalmologic and neuro-otologic disorders |
| A. Neuro-ophthalmology |
| 01. Disorders of the optic nerve |
| a. Vascular (e.g., anterior ischemic optic neuropathy, including giant cell arteritis) |
| b. Inflammatory (e.g., optic neuritis) |
| c. Toxic and nutritional optic nerve disease |
| d. Inherited (e.g., Leber optic atrophy) |
| e. Papilledema and pseudopapilledema |
| 02. Disorders of the retina |
| a. Retinal artery occlusion, including Susac syndrome |
| b. Retinal venous occlusion |
| c. Retinal degenerations |
| d. Phakomatoses |
| 03. Other lesions of optic pathways |
| a. Optic chiasm |
| b. Optic tracts |
| c. Optic radiations |
| d. Visual cortex, including visual agnosias and cortical blindness |
| 04. Disorders of the pupil |
| a. Horner syndrome |
| b. Argyll-Robertson pupil |
| c. Tonic pupil |
| 05. Disorders of ocular motility |
| a. Disorders of supranuclear control of eye movements |
| i. Horizontal gaze palsy, including internuclear ophthalmoplegia (INO) and one-and-a-half syndrome |
| ii. Upgaze palsy, including Parinaud syndrome |
| iii. Downgaze palsy |
| b. Disorders of cranial nerves 3,4, 6, and their nuclei |
| c. Nystagmus |
| B. Neuro-otology |
| 01. Vestibular disease |
| a. Benign positional vertigo |
| b. Ménière disease |
| c. Acute labyrinthitis |
| d. Toxic vestibulopathy |
| e. Cerebellopontine angle tumors |
| f. Central vertigo, including disembarkment syndrome |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 02. Deafness, including inherited and acquired |
| 03. Other, including pulsatile tinnitus |
| 12. Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents |
| A. Metabolic diseases |
| 01. Hypoxic-ischemic encephalopathy |
| 02. Disorders of glucose metabolism, including hypoglycemia, diabetic ketoacidosis, and nonketotic hyperglycemia |
| 03. Hepatic encephalopathy |
| 04. Uremic encephalopathy, including dialysis dementia and dialysis disequilibrium syndrome |
| 05. Disorders of sodium, potassium, and water metabolism, including hyponatremia, hypernatremia, hypokalemia, and hyperkalemia |
| 06. Disorders of calcium and magnesium metabolism, including hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia |
| 07. Endocrine diseases, including those of thyroid, parathyroid, adrenal, and pituitary glands |
| 08. Drug overdose |
| B. Nutritional deficiency states |
| 01. B vitamins |
| a. Thiamine |
| b. Niacin |
| c. Pyridoxine |
| d. Cobalamin |
| e. Folic acid |
| 02. Vitamin E |
| 03. Vitamins A and D |
| 04. Other |
| a. Copper deficiency |
| b. Protein calorie malnutrition |
| c. Strachan syndrome and related disorders |
| d. Complications of bariatric surgery |
| C. Toxins, drugs, and physical agents |
| 01. Occupational exposure to chemicals |
| a. Acrylamide |
| b. Carbon disulfide |
| c. Ethylene oxide |
| d. Hexacarbon solvents |
| e. Organophosphates |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| f. Toluene |
| g. Other |
| 02. Occupational exposure to metals |
| a. Aluminum |
| b. Arsenic |
| c. Lead |
| d. Manganese |
| e. Mercury |
| f. Thallium |
| g. Tin |
| h. Other |
| 03. Effects of drug abuse |
| a. Opioids |
| b. Cocaine |
| c. Amphetamines |
| d. Sedative-hypnotics |
| e. Inhalants |
| f. Hallucinogens |
| g. Other |
| 04. Effects of alcohol |
| a. Acute alcoholic intoxication |
| b. Alcohol withdrawal syndromes |
| c. Effects related to nutritional deficiency |
| d. Effects of unknown etiology (e.g., Marchiafava-Bignami disease) |
| e. Effects of alcohols other than ethanol (e.g., methyl alcohol and ethylene glycol) |
| 05. Effects of ionizing radiation |
| a. Encephalopathy |
| b. Myelopathy |
| c. Plexopathy |
| 06. Hypothermia and hyperthermia |
| 07. Electric current and lightning |
| 08. Animal and insect neurotoxins |
| a. Snakes |
| b. Spiders |
| c. Scorpions |
| d. Tick paralysis |
| 09. Marine neurotoxins |
| a. Ciguatera fish poisoning |
| b. Puffer fish poisoning |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 10. Plant neurotoxins |
| a. Mushroom poisoning |
| b. Other |
| 13. Neuro-oncologic disorders |
| A. Neoplasms |
| 01. Primary |
| a. Primitive neuroectodermal tumors |
| i. Medulloblastoma |
| ii. Retinoblastoma |
| b. Gliomas |
| i. Astrocytoma |
| (a) Low-grade |
| (i) Pilocytic astrocytoma |
| (ii) Astrocytoma |
| (b) High-grade |
| (i) Anaplastic astrocytoma |
| (ii) Glioblastoma |
| ii. Oligodendroglioma |
| (a) Oligodendroglioma |
| (b) Anaplastic oligodendroglioma |
| iii. Ependymoma |
| (a) Ependymoma |
| (b) Anaplastic ependymoma |
| (c) Myxopapillary ependymoma |
| c. Neuronal tumors |
| i. Central neurocytoma |
| ii. Dysembryoblastic neuroectodermal tumor (DNET) |
| iii. Gangliocytoma |
| iv. Ganglioglioma |
| d. Meningioma |
| e. Nerve sheath tumors |
| i. Schwannoma |
| ii. Neurofibroma |
| f. Primary CNS lymphoma |
| g. Craniopharyngioma |
| h. Pituitary adenoma |
| i. Pineal tumors |
| 02. Secondary |
| a. Metastatic intraparenchymal |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| b. Meningeal carcinomatosis |
| c. Metastases to spine and skull |
| B. Hereditary tumor syndromes |
| 01. Neurofibromatosis |
| 02. Von Hippel-Lindau disease |
| 03. Tuberous sclerosis |
| 04. Cowden syndrome |
| 05. Multiple endocrine neoplasms (MEN) |
| C. Non-metastatic neurologic complications of systemic cancer |
| 01. Paraneoplastic syndromes |
| a. Cerebellar degeneration |
| i. Anti-Hu |
| ii. Anti-Yo |
| iii. Anti-Ri |
| iv. Anti-CRMP-5 |
| b. Encephalomyelitis |
| i. Anti-Hu |
| ii. Anti-Ri |
| iii. Anti-CRMP-5 |
| iv. Anti-Ma |
| v. Anti-NMDAR |
| c. Opsoclonus-myooclonus (anti-Ri) |
| d. Sensory neuronopathy (anti-Hu) |
| e. Neuromuscular junction |
| f. Muscle |
| 02. Vascular disease |
| D. Neurologic complications of cancer treatment |
| 01. Radiation therapy |
| a. Radiation necrosis |
| b. Secondary neoplasms |
| 02. Chemotherapy |
| 14. Behavioral neurology and neurocognitive disorders |
| A. Delirium, dementia, and other cognitive disorders |
| 01. Delirium |
| a. Delirium due to a medical condition |
| b. Substance intoxication delirium |
| c. Substance withdrawal delirium |
| d. Delirium due to multiple etiologies |
| e. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 02. Dementia |
| a. Mild cognitive impairment |
| b. Probably Alzheimer disease |
| c. Vascular dementia |
| d. HIV disease |
| e. Traumatic brain injury |
| f. Frontotemporal disorders |
| g. Dementia due to a medical condition |
| h. Substance/medication-induced dementia |
| i. Multiple etiologies, including metabolic, endocrine, toxic, and neoplastic/paraneoplastic |
| 03. Amnestic disorders |
| 04. Other |
| B. Neurodevelopmental disorders |
| 01. Learning disorders |
| 02. Communication disorders |
| 03. Autism spectrum disorders |
| 04. Attention-deficit and disruptive behavior disorders |
| 05. Other |
| C. Higher cortical function and clinical syndromes |
| 01. Frontal lobe syndromes |
| 02. Aphasia |
| 03. Apraxia |
| 04. Neglect |
| 05. Agnosia |
| 06. Disconnection syndromes |
| D. Other |
| 15. Psychiatric disorders |
| A. Schizophrenia and other psychotic disorders |
| 01. Schizophrenia |
| 02. Brief psychotic disorder |
| 03. Psychotic disorder due to another medical condition |
| 04. Substance/medication-induced psychotic disorder |
| 05. Other |
| B. Depressive disorders |
| 01. Depressive disorders |
| a. Major depressive disorder |
| b. Persistent depressive disorder (dysthymia) |
| c. Depressive disorder due to another medical condition |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| d. Other |
| C. Bipolar and related disorders |
| 01. Bipolar I disorder |
| 02. Bipolar II disorder |
| D. Anxiety disorders |
| 01. Panic disorder |
| 02. Obsessive-compulsive disorder |
| 03. Posttraumatic stress disorder |
| 04. Acute stress disorder |
| 05. Generalized anxiety disorder |
| 06. Anxiety disorder due to another medical condition |
| 07. Substance/medication-induced anxiety disorder |
| 08. Other |
| E. Somatic symptom and related disorders |
| 01. Conversion disorder |
| 02. Pain disorder |
| 03. Somatic symptom disorder |
| 04. Illness anxiety disorder |
| 05. Factitious disorders |
| 06. Other |
| F. Dissociative disorders |
| 01. Dissociative amnesia |
| 02. Other |
| G. Sexual disorders |
| 01. Sexual pain disorders |
| 02. Sexual dysfunction due to a general medical condition |
| 03. Other |
| H. Feeding and eating disorders |
| 01. Anorexia nervosa |
| 02. Bulimia nervosa |
| I. Elimination disorders |
| J. Trauma- and stressor-related disorders |
| K. Other psychiatric disorders |
| 16. Autonomic nervous system disorders |
| A. Disorders of orthostatic tolerance |
| 01. Orthostatic hypotension |
| 02. Postural tachycardia syndrome (POTS) |
| 03. Neurally mediated syncope |
| a. Central causes (emotional) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| b. Reflex causes |
| i. Carotid sinus stimulation |
| ii. Micturition, defecation, coughing |
| iii. Hemodynamic stress |
| B. Peripheral autonomic neuropathies |
| 01. Autoimmune autonomic neuropathy and ganglionopathy |
| 02. Guillain-Barré syndrome (autonomic manifestations) |
| 03. Paraneoplastic autonomic neuropathies |
| 04. Inherited autonomic neuropathies |
| a. Fabry disease |
| b. Porphyria (autonomic manifestations) |
| 05. Autonomic neuropathies due to infectious disease |
| a. Chagas disease |
| b. Leprosy |
| c. Diphtheria |
| d. Botulism (autonomic manifestations) |
| 06. Chronic autonomic neuropathies |
| a. Diabetes |
| b. Amyloidosis |
| c. Sensory neuronopathy (Sjögren syndrome) |
| d. Adie syndrome |
| e. Small-fiber polyneuropathy (autonomic manifestations) |
| 07. Toxic neuropathies |
| a. Vacor |
| b. Hexane |
| c. Ciguatoxin |
| d. Vincristine |
| e. Cisplatin, paclitaxel |
| f. Heavy metals (arsenic, mercury, thallium) |
| C. Autonomic dysfunction in CNS disorders |
| 01. Lewy body disorders |
| 02. Multiple system atrophy |
| 03. Tauopathies |
| 04. Pure autonomic failure |
| 05. Multiple sclerosis |
| 06. Stroke |
| D. Disorders of sweating and thermoregulation |
| 01. Hypothermia |
| 02. Hyperthermia |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 03. Regional hyperhidrosis |
| 04. Hypohidrosis (central and peripheral causes) |
| E. Autonomic disorders of the urogenital system |
| 01. Multiple sclerosis |
| 02. Multiple system atrophy |
| F. Autonomic disorders of the gastrointestinal tract |
| 01. Achalasia |
| 02. Gastroparesis |
| 03. Cyclic vomiting syndrome |
| 04. Intestinal pseudo-obstruction |
| 05. Hirschprung disease |
| G. Visceral sensory disorders |
| 01. Disorders of parasympathetic visceral sensation |
| a. Disorders of taste |
| b. Associated with glossopharyngeal neuralgia |
| 02. Disorders of sympathetic visceral sensation: sympathetic storm in spinal cord transection |
| 03. Disorders of central visceral sensation: insular cortex stroke |
| 17. Normal structure, process, and development through the life cycle |
| A. Infancy through adolescence, including developmental processes, tasks, crises, and transitions (e.g., school entry, peer relations, individuation) |
| B. Adulthood, including developmental processes, tasks, crises, and transitions (e.g., employment, parenting) and acquisition/loss of specific capacities (e.g., menopause) |
| C. Late life, including developmental processes, tasks, crises, and transitions, and acquisition/loss of specific capacities (e.g., cognition, physical endurance) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| Dimension 2 |
|---|
| Physician Competencies and Mechanisms |
| A. Neuroscience and mechanism of disease |
| 01. Neuroanatomy |
| a. Cerebral cortex |
| b. Connecting systems |
| c. Basal ganglia/thalamus |
| d. Brainstem |
| e. Cerebellum |
| f. Cranial nerves |
| g. Spinal cord |
| h. Spinal roots/peripheral nerves |
| i. Ventricular system, CSF |
| j. Vascular |
| k. Neuromuscular junction/muscle |
| l. Autonomic nervous system |
| m. Embryology and neural development |
| n. Pain pathways |
| o. Radiologic anatomy, cerebral blood vessels (angiography or MRA) |
| p. CSF anatomy, physiology, normal and abnormal patterns (cellular, chemical, enzymatic, serologic) |
| q. Other |
| 02. Neuropathology |
| a. Basic patterns of reaction |
| b. Cerebrovascular disease |
| c. Trauma (cranial and spinal) |
| d. Metabolic/toxic/nutritional diseases |
| e. Infections |
| f. Demyelinating diseases/leukodystrophies |
| g. Neoplasms |
| h. Congenital/developmental anomalies |
| i. Degenerative/heredodegenerative disorders |
| j. Myopathies |
| k. Peripheral nerve |
| l. Neuromuscular junction disorders |
| m. Radiologic pathology pertinent to assigned pathology sections |
| n. Other |
| 03. Neurochemistry |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Carbohydrate metabolism |
| b. Lipid metabolism |
| c. Protein metabolism |
| d. Neurotransmitters |
| e. Axonal transport |
| f. Energy metabolism |
| g. Blood-brain barrier |
| h. Biochemistry of membranes/receptors/ion channels |
| i. Neuronal excitation |
| j. Vitamins (general aspects) |
| k. Inborn errors of metabolism |
| l. Electrolytes and minerals |
| m. Neurotoxins |
| n. Free radical scavengers |
| o. Excitotoxicity |
| p. Normal CSF constituents and volume |
| q. Other |
| 04. Neurophysiology |
| a. Membrane physiology |
| b. Synaptic transmission |
| c. Sensory receptors and perception |
| d. Special senses |
| e. Reflexes |
| f. Segmental and suprasegmental control of movement |
| g. Cerebellar function |
| h. Reticular system: mechanisms of sleep and arousal, consciousness, circadian rhythms |
| i. Rhinencephalon; limbic system; visceral brain |
| j. Learning and memory |
| k. Cortical organization and function |
| l. Pathophysiology of epilepsy |
| m. Cerebral blood flow |
| n. Autonomic function |
| o. Blood-brain barrier |
| p. Neurophysiology of the visual system |
| q. Neurophysiology of hearing and vestibular function |
| r. Physiology of pain |
| s. Physiology of peripheral nerve and muscle |
| t. Other |
| 05. Neuroimmunology/neuroinfectious disease |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Molecular pathogenesis of multiple sclerosis |
| b. Molecular neurology of prion and infectious diseases |
| c. Immunotherapy in multiple sclerosis, myasthenia gravis, and other neurologic disorders |
| d. Other |
| 06. Neurogenetics/molecular neurology, and neuroepidemiology |
| a. Mendelian-inherited diseases |
| b. Other modes of inheritance |
| c. Mitochondrial disorders |
| d. Trinucleotide repeat disorders |
| e. Channelopathies |
| f. Genetics of epilepsy |
| g. Risk factors in neurologic disease |
| h. Demographics of neurologic disease |
| 07. Neuroendocrinology |
| a. Thyroid gland |
| b. Cushing syndrome |
| c. Corticosteroids |
| d. Growth hormones |
| e. Hypothalamic function |
| f. Adrenal gland |
| g. Pituitary gland |
| h. Prolactin |
| i. Androgen |
| B. Clinical aspects of neurologic disease |
| 01. Epidemiology |
| 02. Risk factors |
| 03. Signs and symptoms |
| 04. Comorbidities |
| 05. Course of illness |
| 06. Prognosis |
| C. Diagnostic procedures |
| 01. Neuroimaging |
| a. Structural imaging (computed tomography, magnetic resonance imaging) |
| b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, ultrasound) |
| c. Functional neuroimaging, including fMRI, SPECT, PET |
| 02. EEG (routine EEG, LTME, subdural and cortical EEGs) |
| 03. Magnetoencephalography |
| 04. Evoked potentials, including intraoperative monitoring |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 05. Sleep studies, including PSG and MSLT |
| 06. EMG/NCS, including SFEMG |
| 07. Autonomic function testing |
| 08. CSF examination |
| 09. Laboratory studies |
| 10. Neuropsychological and cognitive testing |
| 11. Other |
| D. Treatment |
| 01. General principles of neuropharmacology |
| a. Neuropharmacokinetics/neuropharmacodynamics |
| b. Drug toxicity |
| c. Drug interactions |
| d. Teratogenicity |
| e. Age, gender and ethnicity issues |
| f. Pharmacogenomics |
| 02. Pharmacotherapy |
| a. Drugs for migraine and other headache syndromes |
| b. Analgesics (nonnarcotic, narcotic, etc.) |
| c. Anti-seizure medications |
| d. Drugs for sleep disorders |
| e. Drugs for cerebrovascular disease, including antiplatelet agents, anticoagulants, and thrombolytics |
| f. Drugs for neuromuscular junction disorders (cholinesterase inhibitors, DAP, etc) |
| g. Drugs for movement disorders |
| h. Drugs for multiple sclerosis (disease-modifying therapy and symptomatic treatment) |
| i. Drugs for psychiatric disorders (sedative-hypnotics, antianxiety agents, antidepressants, antipsychotics) |
| j. Vitamins |
| k. Immunomodulatory agents, including oral medications, IV Ig, and plasma exchange |
| l. Antimicrobial agents |
| m. Drugs used for increased intracranial pressure |
| n. Other |
| 03. Endovascular treatment |
| 04. Neuromodulation |
| a. VNS |
| b. DBS |
| c. TENS |
| d. Spinal cord stimulation |
| e. TMS |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| f. ECT |
| 05. Critical care |
| 06. Surgical treatment |
| 07. Radiation therapy |
| 08. Rehabilitation |
| a. Exercise |
| b. Assistive devices |
| c. Assistive technologies |
| d. Braces |
| e. Physical therapy and occupational therapy |
| f. Pulmonary |
| g. Speech/swallowing |
| h. Nutrition management |
| 09. Psychotherapy, biofeedback etc. |
| 10. Other |
| E. Interpersonal and communications skills |
| 01. Communication with patients |
| 02. Communication with patients' families |
| 03. Communication with other professionals |
| 04. Communication with the healthcare team |
| 05. Communication with the public |
| 06. Management of conflict |
| 07. Common errors in communication |
| F. Professionalism |
| 01. Professional behavior |
| 02. Adherence to ethical principles (e.g., informed consent, research issues, clinical care) |
| 03. Participation in the professional community |
| 04. Sensitivity to diverse patient populations |
| 05. End-of-life issues and brain death |
| 06. Fatigue management |
| G. Practice-based learning and improvement |
| 01. Development and execution of lifelong learning |
| a. Self-assessment and self-improvement |
| b. Use of evidence-based guidelines |
| c. Critical review of the scientific literature |
| 02. Formal practice-based quality improvement |
| H. Systems-based practice |
| 01. Patient safety and the healthcare team |
| a. Medical errors and their prevention |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| b. Communication in patient safety |
| c. Regulatory and educational activities related to patient safety |
| 02. Resource management |
| a. Parity |
| b. Access to care |
| 03. Community-based care |
| a. Community-based programs |
| b. Prevention |
| c. Recovery and rehabilitation |
| d. Knowledge of the legal aspects of neurological practice |